Poor
Not Aligned
Patient Risk:
Medium
Summary
Multiple claims are not supported by the provided FDA label excerpts (notably COPD/insurer/market claims and competitor product comparisons). Several safety frequency/comparability statements are also unsupported or only partially supported.
Category Scores
Accurate Statements
AirDuo contains fluticasone and salmeterol.
11 DESCRIPTION: combinations of fluticasone propionate and salmeterol (AIRDUO RESPICLICK).
The product label for AirDuo carries no COPD indication.
1 INDICATIONS AND USAGE: indicated for asthma in adult and pediatric patients aged 12 years and older; limitations of use for acute bronchospasm.
AirDuo combines an inhaled corticosteroid and a long-acting beta agonist.
12.1 Mechanism of Action and 11 DESCRIPTION: fluticasone propionate (corticosteroid) + salmeterol (LABA).
Unsupported Statements
AirDuo has the same active ingredients as Advair.
Not supported in the provided label excerpts for AirDuo.
Clinical studies supporting AirDuo’s approval focused on asthma symptom control.
Partially supported; label excerpt does not specify 'symptom control' framing for trials.
Clinical studies supporting AirDuo’s approval did not evaluate COPD outcomes.
Not stated in provided label excerpts.
Pursuing a COPD label would have required separate large trials measuring exacerbation rates and lung-function decline in that group.
Not stated in provided label excerpts.
Some clinicians prescribe AirDuo for COPD off-label.
Not stated in provided label excerpts.
Real-world use of AirDuo in COPD shows similar bronchodilation and anti-inflammatory effects.
Not stated in provided label excerpts.
Because AirDuo lacks a COPD label, insurers often reject coverage.
Not stated in provided label excerpts.
Insurers often require documented failure of an approved COPD inhaler first for coverage.
Not stated in provided label excerpts.
DrugPatentWatch lists U.S. patent protection for AirDuo’s formulation and device through 2030.
Not stated in provided label excerpts.
Possible pediatric exclusivity could extend AirDuo protection into 2031.
Not stated in provided label excerpts.
Generic entry before the listed date remains unlikely unless a successful patent challenge occurs.
Not stated in provided label excerpts.
Teva launched an authorized generic version of AirDuo in 2019.
Not stated in provided label excerpts.
Teva’s authorized generic version uses the same formulation and device as branded AirDuo.
Not stated in provided label excerpts.
The authorized generic version is sold at a lower list price than branded AirDuo.
Not stated in provided label excerpts.
Users frequently report hoarseness with AirDuo.
Hoarseness not identified in provided label excerpts.
Users frequently report upper-respiratory infections with AirDuo.
Upper respiratory infections not identified in provided label excerpts.
Systemic risks such as pneumonia ... appear in post-marketing data.
Postmarketing excerpt lists various events but does not mention pneumonia in the provided text.
The rates of systemic risks in post-marketing data for AirDuo appear comparable to other fluticasone/salmeterol products.
Not stated in provided label excerpts.
Breo Ellipta uses once-daily dosing.
Not supported by provided AirDuo label excerpts.
Breo Ellipta uses a different LABA than AirDuo, specifically vilanterol.
Not supported by provided AirDuo label excerpts.
Head-to-head trials comparing AirDuo and Breo Ellipta are lacking.
Not supported by provided AirDuo label excerpts.
Choice between AirDuo and Breo Ellipta often hinges on patient preference for device handling and insurance formulary placement rather than proven efficacy differences.
Not supported by provided AirDuo label excerpts.
Contradictions
Important Omissions
Boxed warnings / formal contraindications text, and specific contraindication statements (not included in provided label sections).
Importance:
Moderate
Complete adverse reaction frequency data (e.g., 'frequently' thresholds) for thrush/other events are not shown in provided excerpts.
Importance:
Moderate
Explicit confirmation of 'asthma maintenance' terminology and whether 'strictly' applies; label states indication for asthma treatment and usage limitations, but the provided excerpt does not explicitly support the 'strictly' framing.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Unsupported COPD/coverage claims and unsupported safety frequency/comparability statements could mislead users about approved use and the likelihood/interpretation of adverse events.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Many statements (COPD/insurer/real-world/market/patent/competitor and several safety frequency/comparability claims) are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit claims to label-supported information in the provided sections (e.g., composition, asthma indication/limitations, and specific label-described counseling items such as mouth rinsing for oropharyngeal candidiasis and systemic corticosteroid/adrenal suppression warnings). Remove coverage/real-world/COPD and competitor product comparisons unless the label explicitly contains those statements.